Halozyme Therapeutics (HALO) Other Non-Current Liabilities (2013 - 2026)

Halozyme Therapeutics (HALO) has 14 years of Other Non-Current Liabilities data on file, last reported at $106.4 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $106.4 million, up 88.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $106.4 million (up 88.62% YoY), and the FY2025 annual result was $113.9 million, up 107.94% from the prior year.
• Other Non-Current Liabilities fell to $106.4 million in Q1 2026 per HALO's latest filing, from $113.9 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $113.9 million in Q4 2025 and troughed at $171000.0 in Q1 2022.
• A 5-year average of $43.2 million and a median of $34.5 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities slumped 93.91% in 2022, then surged 17194.15% in 2023.
• A 5-year view of Other Non-Current Liabilities shows it stood at $15.5 million in 2022, then surged by 143.8% to $37.7 million in 2023, then soared by 45.17% to $54.8 million in 2024, then jumped by 107.94% to $113.9 million in 2025, then declined by 6.51% to $106.4 million in 2026.
• Business Quant data shows HALO's Other Non-Current Liabilities at $106.4 million in Q1 2026, $113.9 million in Q4 2025, and $71.8 million in Q3 2025.